News
-
DigiSanté: Exchange on the national programme for digitisation in the healthcare sector
-
Electronic patient record (EPR): Federal Council submits dispatch on transitional financing to parliament
-
Swissmedic Journal 08/2023
-
Complementary and herbal medicines containing ethanol in paediatric populations
-
Implementation of the full declaration for homeopathic and anthroposophic medicinal products without indication
-
With immediate effect, Covid certificates will no longer be issued
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC)
-
Smart Pills – Qualification under the Swiss legislation on therapeutic products Innovation in the field of tension between regulatory, scientific and economic interdependencies
-
The Federal Office of Public Health (FOPH) has issued new information letters regarding the obligation to pass on discounts under the Health Insurance Act (HIA)
-
Health insurance: The risk compensation statistics will be expanded
-
Health Technology Assessment (HTA) programme: Review of medical services curbs healthcare costs
-
Treatment recommendations for post-Covid 19 disease
-
Authorisation application submitted for coronavirus vaccine Nuvaxovid XBB.1.5
-
Comirnaty: European Medicines Agency (EMA) recommends approval of adapted COVID-19 vaccine targeting Omicron XBB. 1.5
-
Advisory Board Digital Switzerland: Exchange on national program for the digitization of the healthcare system
-
Federal Council to launch training offensive in the nursing sector in mid-2024
-
Direct Healthcare Professional Communications (DHPC) - Valproate (Depakine®, Depakine Chrono®, Valproate Chrono Sanofi®, Valproate Chrono Desitin®, Orfiril® long, Orfiril®, Valproate Sandoz®, Convulex®)
-
Evaluation of health care for asylum seekers
-
Benchmarking study 2022
-
European Medicines Agency (EMA) review of data on paternal exposure to valproate
-
Decision 9C_326/2023 dated 20 July 2023